Suicidality and antiepileptic drugs: Is there a link?

Drug Safety

Volumn 30, Issue 2, 2007, Pages 123-142

  Kalinin, Vladimir V ^a,b  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b Moscow Research Institute of Psychiatry   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SEROTONIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; AGITATION; ANXIETY; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BRAIN REGION; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; DELUSIONAL DISORDER; DEMENTIA; DEPRESSION; DRUG DOSE ESCALATION; DRUG MECHANISM; DYSPHORIA; EMOTION; EPILEPSY; FOCAL EPILEPSY; HALLUCINATION; HOSTILITY; HUMAN; HYPERACTIVITY; MAJOR DEPRESSION; MENTAL INSTABILITY; MONOTHERAPY; MOOD DISORDER; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SEROTONIN METABOLISM; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE;

AFFECT; ANTICONVULSANTS; BRAIN; COGNITION; COGNITION DISORDERS; DEPRESSION; EPILEPSY; FEMALE; HUMANS; MALE; PERSONALITY DISORDERS; RISK FACTORS; SEROTONIN; SUICIDE;

EID: 33846657659     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730020-00003     Document Type: Review

References (156)

1. Diehl LW. Epilepsie und Suizid. Psychiatr Neurol Med Psychol (Leipz) 1986; 38: 625-33
2. Blumer D. Postictal depression: significance for the neurobehavioral disorder of epilepsy. J Epilepsy 1992; 5: 214-9
3. Blumer D, Montouris G, Davis K, et al. Suicide in epilepsy: psychopathology, pathogenesis, and prevention. Epilepsy Behav 2002; 3 (3): 232-41
4. Blumer D. Dysphoric disorders and paroxysmal affects: recognition and treatment of epilepsy-related psychiatric disorders. Harvard Rev Psychiatry 2000; 8 (1): 8-17
5. Mendez MF, Cummings JL, Benson DE. Depression in epilepsy: significance and phenomenology. Arch Neurol 1986; 43: 766-70
6. Robertson MM, Trimble MR, Townsend HRA. Phenomenology of depression in epilepsy. Epilepsia 1987; 28: 364-72
7. Lambert MV, Schmitz EB, Ring HA, et al. Neuropsychiatric aspects of epilepsy. In: Schiffer RB, Rao SM, Fogel BS, editors. Neuropsychiatry. 2nd ed. Philadelphia (PA): LWW, 2003: 1071-131
8. Lambert MV, Thompson PJ, Trimble M. Neuropsychiatric aspects of epilepsy. In: Rizzo M, Eslinger PJ, editors. Principles and practice of behavioral neurology and neuropsychology. Philadelphia (PA): Saunders, 2004: 763-79
9. Kalinin V, Polyanskiy D. Gender differences in risk factors of suicidal behavior in epilepsy. Epilepsy Behav 2005; 6: 424-9
10. Kalinin V, Polyanskiy D. Gender and suicidality prediction in epilepsy. Epilepsy Behav 2005; 7, 4: 657-63
11. Steinert T, Fröscher W. Aggression bei Epilepsie. Nervenheilkd 1994; 13: S199-205
12. Rösche J, Uhlmann C, Möller A. Psychische Störungen. In: Fröscher W, Vassella F, Hufnagel A. (Hrsgb.) Die Epilepsien. Grundlagen, Klinik, Behandlung. Stuttgart: Schattauer, 2004: 243-62
13. Kanner A, Rivas Nieto JC. Depressive disorders in epilepsy. Neurology 1999; 53 Suppl. 1: S26-32
14. Attarian H, Vahle V, Carter J, et al. Relation between depression and intractability of seizures. Epilepsy Behav 2003; 4: 298-301
15. Kanner A. Depression in epilepsy is much more than a reactive process. Epilepsy currents 2003; 3 (3): 202-3
16. Harden CL, Goldstein MA. Mood disorders in patients with epilepsy: epidemiology and management. CNS Drugs 2002; 16 (5): 291-302
17. Altshuler LL, Devinsky O, Post RM, et al. Depression, anxiety and temporal lobe epilepsy: laterality of focus and symptoms. Arch Neurol 1990; 47: 284-8
18. Mendez MF, Taylor JL, Doss RC, et al. Depression in secondary epilepsy: relation to lesion laterality. J Neurol Neurosurg Psychiatry 1994; 57: 232-3
19. Victoroff JL, Benson F, Grafton ST, et al. Depression in complex partial seizures: electroencephalography and cerebral metabolic correlates. Arch Neurol 1994; 51: 155-63
20. Schmitz B. Depressive disorders in epilepsy. In: Trimble M, Schmitz B, editors. Seizures, affective disorders and anticonvulsant drugs. Guildford: Clarius Press Ltd, 2002: 19-34
21. Ritaccio AL, Devinsky O. Personality disorders in epilepsy. In: Ettinger A, Kanner A, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Philadelphia (PA): LWW, 2001: 147-61
22. Doval O, Gaviria M, Kanner A. Frontal lobe dysfunction in epilepsy. In: Ettinger A, Kanner A, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Philadelphia (PA): LWW, 2001: 261-71
23. Castellon SA, Hinkin CH, Satz P. Behavioral disorders associated with central nervous system dysfunction. In: Adams HE, Sutker PB, editors. Comprehensive handbook of psychopathology. 3rd ed. New York: Springer, 2004: 813-40
24. Herman BP, Seidenberg M, Haltiner A, et al. Mood state in unilateral temporal lobe epilepsy. Biol Psychiatry 1991; 30: 1205-18
25. Schneider F, Habel U, Bestman S. Affektive Störungen. In: Förstl H. (Hrsg.) Frontalhirn. Funktionen und Erkrankungen, 2 Auflage. Heidelberg: Springer, 2005: 233-65
26. Helmstaedter C, Sonntag-Dillender M, Hoppe C, et al. Depressed mood and memory impairment in temporal lobe epilepsy as a function of focus lateralization and localization. Epilepsy Behav 2004; 5 (5): 696-701
27. Quiske A, Helmstaedter C, Lux S, et al. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000; 39: 121-5
28. Conwell Y, Burhan A. The neuropsychiatry of suicide. In: Schiffer RB, Rao SM, Fogel BS, editors. Neuropsychiatry. 2nd ed. Philadelphia (PA): LWW, 2003: 679-723
29. Asberg M, Thoren P, Traskman L, et al. "Serotonin depression": a biochemical subgroup within the affective disorder? Science 1976; 191: 478-80
30. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 1976; 33: 1193-7
31. Agren H. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: II. Suicide. Psychiatry Res 1980 Oct; 3 (2): 225-35
32. Brown GL, Goodwin FK, Ballenger JC, et al. Aggression in human correlates with cerebrospinal fluid metabolites. Psychiatry Res 1979; 1: 131-9
33. Brown GL, Ebert ME, Goyer PF, et al. Aggression, suicide and serotonin: relationships to CSF amine metabolites. Am J Psychiatry 1982; 139: 741-6
34. Lidberg L, Tuck JR, Asberg M, et al. Homocide, suicide and CSF 5-HIAA. Acta Psychiatr Scand 1985; 71: 230-6
35. Linnoila VM, Virkkunen M. Aggression, suicidality, and serotonin. J Clin Psychiatry 1992; 53 Suppl.: 46-51
36. van Praag HM. Biological suicide research: outcome and limitations. Biol Psychiatry 1986; 21 (13): 1305-23
37. van Praag HM, Plutchik R. Depression type and depression severity in relation to risk of violent suicide attempt. Psychiatry Res 1984; 12: 333-8
38. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; 1: 214-6
39. Janicak PG, Davis JM, Preskorn SH, et al. Principles and practice of psychopharmacotherapy. Philadelphia (PA): LWW, 2001: 700
40. Chugani HT, Chugani DC. Imaging of serotonin mechanisms in epilepsy. Epilepsy Currents 2005; 5 (6): 201-6
41. Dailey JW, Reigel CE, Mishra PK, et al. Neurobiology of seizure predisposition in the genetically epilepsy-prone rat. Epilepsy Res 1989; 3: 317-20
42. Statnick MA, Daile JW, Jobe PC, et al. Abnormalities in brain serotonin concentration, high-affinity uptake, and tryptophan hydroxylase activity in severe-seizure genetically epilepsy-prone rats. Epilepsia 1996; 37: 311-21
43. Wenger GR, Stitzel RE, Craig CR. The role of biogenic amines in the reserpine-induced alteration of minimal electroshock seizure thresholds in the mouse. Neuropharmacology 1983; 12: 693-703
44. Maynert E, Marczynski T, Browning R. The role of neurotransmitters in the epilepsies. Adv Neurology 1975; 13: 79-143
45. Louw D, Sutherland GB, Glavin GB, et al. A study of monoamine metabolism in human epilepsy. Can J Neurol Sci 1989; 16: 394-7
46. Bercovici E, Cortez MA, Wang X, et al. Serotonine depletion attenuates AY-9944-mediated atypical absence seizures. Epilepsia 2006; 47 (2): 240-6
47. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biological Psychiatry 1999; 46: 1375-87
48. Gilliam F, Santos J, Vahle V, et al. Depression in epilepsy: ignoring clinical expression of neuronal network dysfunction? Epilepsia 2004; 45 Suppl. 2: 28-33
49. Forsgren L, Nystrom L. An incident case referent study of epileptic seizures in adults. Epilepsy Res 1990; 6: 66-81
50. Hesdorffer DC, Hauser WA, Annegers JF, et al. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000; 47: 246-9
51. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53 Suppl. 2: 53-67
52. Hirsch E, Schmitz B, Carreňo M. Epilepsy, antiepileptic drugs (AEDs) and cognition. Acta Neurologica Scand 2003; 108 Suppl. 180: 23-32
53. Frances A, Manning D, Marin D, et al. Relationship of anxiety and depression. Psychopharmacology 1992; 106 Suppl.: S82-86
54. Brent D, Crumrine P, Varma R. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80: 909-17
55. Ferrari N, Barabas G, Mathews W. Psychological and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. Am J Psychiatry 1983; 140: 112-3
56. Smith D, Collins J. Behavioral effects of carbamazepine, phenobarbital, phenitoin and primidone [abstract]. Epilepsia 1987; 28: 598
57. Barabas G, Mathews W. Barbiturate anticonvulsant as a cause of severe depression. Pediatrics 1988; 82: 284-5
58. Hawton K, Fagg J, Marsack P. Association between epilepsy and attempted suicide. J Neurol Neurosurg Psychiatry 1980; 43: 168-70
59. Calandre EP, Dominguez-Granados R, Gomez-Rubio M, et al. Cognitive effects of long-term treatment with Phenobarbital and valproic acid in school children. Acta Neurologica Scandinavica 1990; 81: 504-6
60. Kanner A, Weisbrot D. Psychiatric evaluation of the patient with epilepsy: a practical approach for the "Nonpsychiatrists". In: Ettinger A, Kanner A, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Philadelphia (PA): LWW, 2001: 19-43
61. Brown SW. Dementia and epilepsy. In: Trimble M, Schmitz B, editors. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press, 2002: 135-51
62. Barry JJ, Lembke A, Huynh N. Affective disorders in epilepsy. In: Ettinger A, Kanner A, editors. Psychiatric issues in epilepsy: a practical guide to diagnosis and treatment. Philadelphia (PA): LWW, 2001: 45-71
63. Barry JJ. The recognition and management of mood disorders as a comorbidity of epilepsy. Epilepsia 2003; 44 Suppl. 4: 30-40
64. Reynolds E, Chanarin I, Milner G, et al. Anticonvulsant therapy, folic acid and vitamin B12 metabolism and mental symptoms. Epilepsia 1966; 7: 261-70
65. Fröscher W, Maier V, Laage M, et al. Folate deficiency, anticonvulsant drugs, and psychiatric morbidity. Clin Neuropharmacol 1995; 18: 165-82
66. Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995; 36 Suppl. 2: 46-65
67. Devinsky O, D'Esposito M. Neurology of cognitive and behavioral disorders. New York: Oxford University Press, 2004: 451
68. Biggs CS, Pearce BR, Fowler LJ, et al. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992; 59: 1702-8
69. Parnas J, Flachs H, Gram L. Psychotropic effect of antiepileptic drugs. Acta Neurologica Scand 1979; 60: 329-43
70. Lefkowitz MM. Effects of diphenylhydantoin on disruptive behaviour. Arch Gen Psychiatry 1969; 20: 643-51
71. Malitz S, Kanzler M. Are antidepressants better than placebo? Am J Psychiatry 1971 Jun; 127 (12): 1605-11
72. Aldenkampf AP. Antiepileptic drug treatment and epileptic seizure effect on cognitive function. In: Trimble M, Schmitz B, editors. The Neuropsychiatry of Epilepsy. Cambridge: Cambridge University Press, 2002: 256-267
73. Aldenkampf AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003; 44 Suppl. 4: 21-9
74. Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Behav 2004; 5 Suppl. 1: 60-5
75. Reijs R, Aldenkampf AP, De Krom M. Mood effects of antiepileptic drugs. Epilepsy Behav 2004; 5 Suppl. 1: 66-76
76. Yan QS, Mishra PK, Burger RL, et al. Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats. J Pharmacol Exp Ther 1992; 261: 652-9
77. Dailey JW, Reith ME, Yan QS, et al. Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodoxin or zero Ca2+. Eur J Pharmacology 1997; 328: 153-62
78. Grunze H, Amann B, Walden J. How might anticonvulsant drugs work in bipolar affective disorders. In: Trimble M, Schmitz B, editors. Seizures, affective disorders and anticonvulsant drugs. Guildford: Clarius Press Ltd, 2002: 117-30
79. Mclean MJ. Oxcarbazepine. Mechanisms of action. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 452-8
80. Kanner A. Is major depression a neurologic disorder with psychiatric symptoms? Epilepsy Behav 2004; 5: 636-44
81. Jobe P, Browning R. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 2005; 7: 602-19
82. Stein G. Drug treatment of the personality disorders. British J Psychiatry 1992; 161: 167-84
83. Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971; 12: 325-34
84. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977; 27: 1023-8
85. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine and phenytoin: a reanalysis. Neurology 1991; 41: 141-3
86. Bialer M. Oxcarbazepine. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 459-65
87. Clinckers R, Smolders I, Meurs A, et al. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepin: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharm Exp Ther 2005; 314: 725-31
88. Besag FM. Behavioral effect of the new anticonvulsants. Drug Saf 2000; 24: 513-36
89. Aikia M, Kälviäinen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Research 1992; 11: 199-203
90. Laaksonen R, Kaimola K, Grahn-Teräväionen E, et al. A controlled clinical trial of the effects of carbamazepine and oxcarbazepine on memory and attention [abstract]. 16th International Epilepsy Congress; 1985 Sep 6-9; Hamberg
91. Sabers A, Moller A, Dam M, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995; 92: 19-27
92. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacology 1993; 44: 529-33
93. Gillham RA, McKee PJW, Brodie MJ. Oxcarbazepine and cognitive function after a single dose and during double-blind placebo-controlled cross-over study [abstract]. Epilepsia 1993; 34 Suppl. 2: 122
94. Krämer G. Oxcarbazepine. Adverse effects. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 479-86
95. Lösher W. Valproic acid. Mechanisms of action. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 767-79
96. Whitton PS, Oreskovic D, Jernej B, et al. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain. J Pharm Pharmacology 1985; 37: 199-200
97. Maes M, Calabrese J, Jayathilake K, et al. Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Res 1997; 71: 67-76
98. Swann AC. Valproic acid: clinical efficacy and use in psychiatric disorders. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic Drugs. 5th edition. Philadelphia (PA): LWW, 2002: 828-36
99. Pies R, Adler DA, Ehrenberg BL. Sleep disorders and depression with atypical features: response to valproate. J Clin Psychopharmacology 1989; 9: 352-7
100. Kemp LI. Sodium valproate as an antidepressant. Br J Psychiatry 1992; 160: 121-3
101. Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bulletin 1996; 32: 647-52
102. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J. Clin Psychiatry 2001; 62: 199-203
103. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000; 61: 123-8
104. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59: 676-80
105. Trimble MR, Tompson PJ. Sodium valproate and cognitive function. Epilepsia 1984; 25 Suppl. 1: S60-4
106. Genton P, Gelisse P. Valproic acid: adverse effects. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 837-51
107. Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning: comparison with carbamazepine. Arch Neurology 1996; 53: 1008-16
108. Privitera MD, Twyman RE. Topiramate: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 740-52
109. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996; 46: 1678-83
110. Faught E, Wilder BJ, Ramsay RE. Topiramate placebo-controlled dose ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684-90
111. White HS. Topiramate: mechanisms of action. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 719-26
112. Thompson PJ, Baxendale SA, Duncan JS, et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatr 2000; 69: 636-41
113. Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Research 1997; 27: 29-32
114. Aldencamp AP, Baker G, Mulder OG, et al. A multicentre randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167-78
115. Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 2003; 44 (12): 1573-7
116. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44: 659-63
117. Gould E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 1999; 21 Suppl.: S46-51
118. Toczek MT, Carson RE, Lang L, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003; 60: 749-56
119. Andermann F. Temporal pole and mesiotemporal epilepsy: introductory remarks. Epileptic disorders 2002; 4 Suppl. 1: S7-8
120. Kahane P, Chabardes S, Minotti L, et al. The role of temporal pole in the genesis of temporal lobe seizures. Epileptic disorders 2002; 4 Suppl. 1: S51-8
121. Abraham G. Topiramate-induced suicidality. Can J Psychiatry 2003; 48 (2): 127-8
122. Shorvon SD. Safety of topiramate: adverse events and relationship to dosing. Epilepsia 1996; 37 (S2): 18-22
123. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 321-34
124. Dimond KR, Pande AC, Lamoreus L, et al. Effect of gabapentin (Neurotin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 407-17
125. Harden CL, Pick LH. Alterations in mood and anxiety in epilepsy patients treated with gabapentin [abstract]. Epilepsia 1996; 37 (5): 137
126. Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999; 40: 1129-34
127. Dodrill CB, Arnett JL, Hayes AG, et al. Cognitive abilities and adjustment with gabapentin: results of multisite study. Epilepsy Res 1999; 35: 109-21
128. Greist JH. Gabapentin: clinical efficacy and use in psychiatric disorders. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 349-59
129. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999; 40: 1279-85
130. Martin R, Meador K, Turrentine L, et al. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 2001; 42: 764-71
131. Hudson JI, Pope HG. Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry 1990; 147 (5): 552-64
132. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607-14
133. Giardina WJ. Tiagabine: mechanisms of action. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 675-80
134. Kälviäinen R. Tiagabine: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 698-704
135. Sveinbjornsdottir S, Sander J, Patsalos P, et al. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994; 3: 29-35
136. Dodrill CB, Arnett JL, Sommerville K, et al. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997; 48: 1025-31
137. Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005, 381
138. Pereira J, Marson AG, Hutton JL. Tiagabine add-on for drug resistant partial epilepsy. Cochrane Database Syst Rev 2002; 3: CD001908
139. Grabowska-Grzyb A, Jedrzejczak J, Naganska E, et al. Risk factors for depression in patients with epilepsy. Epilepsy Behav 2006, 417
140. Ben-Menachem E. Vigabatrin. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 855-63
141. Ferrie CD, Robinson RO, Panayitopoulos CP. Psychotic and severe behavioral reactions with vigabatrin: a review. Acta Neurol Scand 1996; 93: 1-8
142. Leach MJ, Randall AD, Stefani A, et al. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 363-9
143. Southam E, Kirkby D, Higgins GA, et al. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacolology 1998; 358: 19-24
144. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993; 34: 312-22
145. Brodie MJ, Richens A, Yuen AW, for the UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-9
146. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001; 2: 28-36
147. Cramer JA, Hammer AE, Kustra RP. Improved mood states with lamotrigine in patients with epilepsy. Epilepsy Behav 2004; 5: 702-7
148. Cramer JA, Hammer AE, Kustra RP. Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav 2004; 5: 224-30
149. Kockelmann E, Elger CE, Helmstaedter C. Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav 2004; 5: 716-21
150. Cramer JA, Van Hammee G, N132 Study Group. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 2003; 4: 118-23
151. French J, Edrich P, Cramer J. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001; 47: 77-90
152. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61 (5): 704-6
153. Macdonald RL. Zonisamide: mechanisms of action. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 867-72
154. Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005; 19 (4): 347-67
155. Lee BI. Zonisamide: adverse effects. In: Levy RH, Mattson RH, Meldrun B, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): LWW, 2002: 892-8
156. Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000; 9 (1): 65-70